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DNA methylation and the localization and post-
translational modification of nucleosomes are inter-
dependent factors that contribute to the generation
of distinct phenotypes from genetically identical
cells. With 112 whole-genome bisulfite sequencing
datasets from the BLUEPRINT Epigenome Project,
we analyzed the global development of DNA methyl-
ation patterns during lineage commitment and matu-
ration of a range of immune system effector cells
and the cancers that arise from them. We show clear
trends in methylation patterns that are distinct in
the innate and adaptive arms of the human immune
system, both globally and in relation to consistently
positioned nucleosomes. Most notable are a pro-
gressive loss of methylation in developing lympho-
cytes and the consistent occurrence of non-CG
methylation in specific cell types. Cancer samples
from the two lineages are further polarized, sug-
gesting the involvement of distinct lineage-specificCell Repo
This is an open access article undepigenetic mechanisms. We anticipate broad utility
for this resource as a basis for further comparative
epigenetic analyses.INTRODUCTION
Different cell types stably express distinct phenotypes despite
sharing an identical underlying genotype. Chemical modifica-
tions to DNA and associated histones allow genetically identical
cells to exhibit radically different behavior and morphology by
shaping gene expression programs and cellular responses to
stimuli (Luperchio et al., 2014; Peric-Hupkes et al., 2010; Shen
and Laird, 2013).
Well-defined differentiation programs in the hematopoietic
system provide an ideal model to investigate the mechanisms
regulating cell identity. Lineage choice (myeloid or lymphoid) fol-
lowed by further specialization and stable states of quiescence,
activation, or long-term memory offer an established framework
for studying epigenetic processes (Kondilis-Mangum andWade,
2013; Russ et al., 2013). Previous studies examining such
modifications have contributed substantial insights into immunerts 17, 2101–2111, November 15, 2016 ª 2016 The Authors. 2101
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
system function and dysfunction (Cedar and Bergman, 2011;
Farh et al., 2015).
DNAmethylation is a ubiquitous epigenetic mark that is written
directly onto DNA as the addition of a methyl group to a cytosine
residue. Most DNA methylation occurs at cytosines followed by
a guanine residue (CG dinucleotides), and the bulk of CGs
genome-wide are methylated (Lister et al., 2009). Large-scale
methylation patterns distinguish cell types (Hodges et al.,
2011), and stable control of themethylome increases the stability
of a given cell state (Raynal et al., 2012). The spatial organization
and epigenetic patterning of the genome both deteriorate pro-
gressively over the lifetime of an organism (Sinclair and Ober-
doerffer, 2009) and are often markedly disorganized in cancer
and human genetic disorders of premature aging (Heyn et al.,
2013; Reddy and Feinberg, 2013). Epigenetic modifiers, such
as the DNA methyltransferase DNMT3A and the demethylase
TET2, are commonly mutated in cancer (Jasielec et al., 2014;
Shih et al., 2012). Many cancer subtypes have an identifiable
methylation signature (Shen and Laird, 2013), and methylation
patterns of human cells approaching senescence (Cruickshanks
et al., 2013) and of long-lived immunological memory cells and
plasma cells often begin to resemble those commonly observed
in cancer and in immortalized cell lines (Kulis et al., 2012, 2015).
In addition, recent studies have documented the ability of path-
ogens to directly and specifically modulate host epigenomes to
dampen the immune response and enhance their own survival
(Jose et al., 2016; Pacis et al., 2015; Sharma et al., 2015).
Two key components of genomic organization that are re-
flected in, and affected by, methylation are the DNA-binding pro-
tein CTCF (Ong and Corces, 2014; Wang et al., 2012) and nucle-
osomes, the basic structural units of chromatin (Mueller-Planitz
et al., 2013). Across the vast majority of the human genome,
nucleosome positions are not consistent between cells, even
within homogeneous cell populations, as evidenced by the
generally fuzzy picture produced by genome-wide nucleosome
footprinting studies (Gaffney et al., 2012; Valouev et al., 2011).
Exceptions occur in the 1 or 2 kb of DNA surrounding occupied
CTCF-binding sites and in the0.5 kb immediately downstream
of transcription start sites, where regular and consistent nucleo-
some spacing is evident as periodic peaks and valleys in
nuclease-digested read counts (Fu et al., 2008).
Numerous experimental studies support the conclusion that
nucleosomes protect occupied DNA from methylation, directing
it preferentially to adjacent linker regions (Felle et al., 2011; Take-
shima et al., 2008; Zhang et al., 2010), and that methylation dis-
favors nucleosome occupancy (Jimenez-Useche et al., 2013;
Pe´rez et al., 2012; Portela et al., 2013). Those results are consis-
tent with others directly correlating low nucleosome occupancy
with high methylation levels within individual DNA molecules
(Kelly et al., 2012) and across species (Huff and Zilberman,
2014). However, counterexamples exist, describing higher
methylation levels associated with nucleosome occupancy
genome-wide (Chodavarapu et al., 2010; Jin et al., 2012). Con-
flicting reports may be attributable to different levels of data
resolution or quality or to the choice of scale for the analysis.
Areas of phased, consistently positioned nucleosomes sur-
rounding CTCF-binding sites provide an opportunity to investi-
gate the relationship between DNAmethylation and nucleosome2102 Cell Reports 17, 2101–2111, November 15, 2016occupancy at these structurally important sites across a range of
cell types.
To investigate the epigenetic mechanisms guiding cell identity
and to provide a resource for the research community, the
BLUEPRINT Epigenome Project has produced more than 200
whole-genome bisulfite sequencing (WGBS) DNA methylation
maps, as well as genome-wide maps for six histone modifica-
tions, DNase-I hypersensitivity, and RNA expression for the large
majority of these samples, covering the development of the ma-
jor branches of the human immune system and several cancers
that arise from them. Here, we integrated WGBS methylation
maps for each of 112 samples from BLUEPRINT with CTCF-
binding data from ENCODE and nucleosome occupancy derived
from micrococcal nuclease digestion sequencing (MNase-seq)
and chromatin immunoprecipitation sequencing (ChIP-seq)
data from BLUEPRINT samples and ENCODE cell lines.
We follow the development and activation of monocytes/mac-
rophages and neutrophils in the myeloid lineage, and T and B
lymphocytes in the lymphoid branch, and demonstrate consis-
tent lineage-specific differences in the usage of DNAmethylation
globally and in relation to consistently positioned nucleosomes.
We note progressive methylation shifts with differentiation
and methylation trends in cancer samples that become more
distinct between the two lineages. We also describe two distinct
forms of apparent non-CG methylation: diffuse, globally high
levels in naive T cells and uncommitted hematopoietic progeni-
tor cells and dense exon-specific non-conversion in a few sam-




Trends in global average CG methylation are markedly distinct
between the lymphoid andmyeloid lineages (Figure 1). Following
commitment to the myeloid lineage, global average CG methyl-
ation levels remain high and relatively stable throughout differen-
tiation and activation. Slightly higher methylation levels are seen
in macrophages relative to monocytes (t test; monocytes versus
M0: p = 2 3 104; M1: p = 1 3 103; M2: p = 8 3 104), but the
difference is small in comparison to the large differences among
lymphocytes.
In both T and B lymphocytes, global methylation drops pro-
gressively with sequential stages of differentiation, resulting in
the lowest genome-wide methylation levels in long-lived memory
B cells and plasma cells, lymphoid cancers, and experimentally
transformed B cells (Figures 1A and 1B). The dynamics of deme-
thylation in T and B lymphocytes compared with the relatively
constant levels across the myeloid lineage suggests substantially
different usage of DNA methylation between the two lineages.
Non-CG Methylation
Methylation outside of a CG dinucleotide context (mCH, where
H = {A,C,T}) is prevalent in stem cells and neurons but was
believed to be absent from other cell types (Ziller et al., 2011;
Lister et al., 2013). The non-random distribution of mCH in a
range of tissues is now generally accepted (He and Ecker,
2015; Schultz et al., 2015). Most BLUEPRINT samples contain
Figure 1. Genome-wide DNA Methylation
Trends in Cells of the Lymphoid and Myeloid
Lineages
(A) Methylation in CH and CG contexts in lymphoid
(triangles) and myeloid cells (circles). Long-lived
lymphoid cells have lower CG methylation.
Naive T cells have higher levels of non-CG
methylation. Most myeloid-derived cancers gain
non-CG methylation.
(B) CG methylation. Developing lymphocytes lose
methylation (left). Cells of the myeloid lineage are
relatively constant or show small gains in methyl-
ation (right).
(C) Fraction of non-CG cytosines methylated.
Fraction methylated is computed as the number of
significantly methylated non-CG cytosines divided
by the total number of non-CG cytosines read with
adequate coverage to make a methylation call, as
described in Experimental Procedures. Stem cell:
HUES64 cell line; progenitor: CD34+, including
stem cells, multipotent progenitors, and common
lymphoid progenitors. Numbers indicate develop-
mental order relative to the indicated cell type.
Blue, female; red, male.only background levels of mCH, likely reflecting very low levels of
incomplete sodium bisulfite conversion of unmethylated cyto-
sines. We excluded five under-converted samples, and all re-
maining samples had conversion rates greater than 99.7%.
Following exclusion of those samples below this stringentCell Reportthreshold, measured mCH levels are not
influenced by conversion rate (Figure 2C).
We found high levels of mCH in all naive
T cell samples (three CD4+ and three
CD8+) and in uncommitted hematopoietic
progenitor cells (UHPs) (Figure 1C). The
fraction of non-CG cytosines that are
methylated in these samples is signifi-
cantly higher than in other cell types from
either lineage (t test; p = 5.7 3 103) and
is more similar to levels seen in stem cells.
This widespread mCH disappears with
subsequent stages of T cell development.
Macrophage samples (M0, M1, and M2)
also have elevated levels of mCH relative
to most committed cell types but do not
reach the levels seen in progenitors and
naive T cells. Leukemias derived from
the myeloid lineage (acute promyelocytic
leukemia [APL] and acute myeloid leuke-
mia [AML]) appear to consistently gain
considerable mCH (p = 2.8 3 103; t test
relative to all other myeloid samples). In
lymphoid-derived neoplasms (mantle cell
lymphoma [MCL], chronic lymphocytic
leukemia [CLL], and multiple myeloma
[MM]), mCH appears more varied (Fig-
ure 1C). Cancer sample source materials
are described in Table S1.Diffuse mCH is found overwhelmingly in a CA context (>90%),
with CAC accounting for 72%ofmethylated non-CG cytosines in
naive T cells (Figure 2B). CAC is the predominant context of mCH
in neurons, whereas CAG is more common in the H1 stem cell
line (Lister et al., 2009; Schultz et al., 2015; Varley et al., 2013).s 17, 2101–2111, November 15, 2016 2103
Figure 2. Non-CG Methylation
(A) Example of mCH exclusion from lamina-associated domains (shaded
areas) in a naive T cell, chr10:100,600,000–124,600,000. x axis, genomic
location; y axis, non-CG methylation level (negative values, minus strand;
positive values, plus strand). CpG islands (vertical blue bars) and CTCF-
binding sites (red triangles) are shown.
(B) Information content in the sequence context of mCH in naive T cells. The
methylated cytosine is at position 6.
(C) Conversion rate andmCH. After exclusion of under-converted outliers (red,
top plot), the fraction of methylated non-CG cytosines is not influenced by
conversion rate (bottom expanded plot), as determined using unmethylated
spiked-in bacteriophage DNA. mCH is computed as the fraction of non-con-
verted non-CG cytosines.
Figure 3. Exon-Specific CH Non-conversion
Two plots at the same genomic location (x axis) at different resolutions. (Top
plot) Spikes rise above background mCH levels. (Bottom plot) Spikes are
specific to exons (blue boxes). y axis, fraction of non-converted reads at non-
CG cytosines. Negative values indicate cytosines on the minus strand. Only
positions with six or more reads informative for methylation status are shown.
See also Figure S1.In all hematopoietic samples where it occurs at appreciable
levels, non-CG methylation is enriched in genes (exons and/or
introns), to varying degrees. At the scale of whole chromosomes,
the most distinctive feature of the high levels of mCH is their
exclusion from lamina-associated domains (LADs) (Figure 2A;
p < 106). Because LADs cover 1/3 of the genome and are
gene poor, mCH exclusion from these regions may contribute
to the observed enrichment in genes.
In addition to the diffusemCH seen in all uncommitted progen-
itors and naive T cells, we also noticed short contiguous regions
of non-CG cytosines protected from bisulfite conversion that are
localized precisely to exons in one of the two MCL samples and
in two normal samples (Figure 3). These spikes in non-converted
non-CG cytosines occur in three and sixteen exons in a neutro-
phil and monocyte sample, respectively, and in more than 400
exons and pseudogenes in theMCL sample. As shown in the ex-
amples in Figure S1, the putative mCH spikes occur at areas of2104 Cell Reports 17, 2101–2111, November 15, 2016transition in CG methylation levels. Although striking, we note
that these mCH spikes are not observed in other samples of
the same cell types, making it impossible to draw robust conclu-
sions with the limited examples currently available.
DNA Methylation Reflects Nucleosome Positioning
In all samples, DNA methylation levels near CTCF display an
oscillatory pattern with a period of approximately 175 bp, consis-
tent with one unit of nucleosome-occupied DNA plus one linker
segment (Fu et al., 2008). We compared methylation levels
with experimentally determined nucleosome occupancy data
from previously published studies using MNase-seq (Valouev
et al., 2011) and nucleosome positions derived from ChIP-seq
experiments using BLUEPRINT samples (Mammana et al.,
2013). Methylation and nucleosome occupancy oscillate in
counterphase, with peaks in methylation corresponding to
valleys in nucleosome density (Figure 4A). In contrast with other
results (Teif et al., 2014), the bias for increased methylation be-
tween nucleosomes is consistent both within and outside of
CpG islands (Figure S2), although levels of both methylation
and nucleosome occupancy are generally lower within CpG
islands.
Figure 4. DNA Methylation Levels at Successive Stages of B Lymphocyte Development Aggregated across Subsets of CTCF-Binding Sites
Development occurs in the order indicated in the legend, with UHP being the least differentiated cell type.
(A) Methylation surrounding 23,710 constitutively occupied CTCF-binding sites shows oscillations that increase in amplitude as lymphocytes develop.
(B–D) CTCF-binding sites specifically occupied in (B) lymphoblastoid cell line, (C) stem cell line (unoccupied in B cells), and (D) skin cell line (unoccupied in B cells).
GC, germinal center B cell; PC, plasma cell; UHP, uncommitted hematopoietic progenitor. See also Figures S2 and S3.We separated CTCF-binding sites into those which are consti-
tutively occupied (cCTCF), occupied only in specific cell types,
or unoccupied, as in Li et al. (2013), revealing that oscillating
methylation levels are driven by the constitutively occupied sites
(Figure 4). Although occupied cell-type-specific binding sites
display a valley in average methylation levels, most have little
or no discernible oscillatory pattern (Figure 4B). Stem cell lines
(H1 and H9) are the exception, where methylation near the
stem-cell-specific CTCF sites also displays the clear oscillatory
pattern characteristic of cCTCF sites (Figure S3C). Unoccupied
CTCF sites display minimal oscillation and a much less pro-
nounced dip in methylation immediately surrounding the binding
site (Figures 4C and 4D).
In each sample where it occurs, mCH follows a similar nucle-
osome-influenced spatial enrichment pattern as CG methylation
near cCTCF, but the bias for mCH toward linker regions is even
more pronounced than for CG methylation, with almost com-
plete exclusion from nucleosome-occupied DNA (Figure 5).
Aggregate methylation levels are similar on the plus and minus
strands relative to the orientation of the CTCF motif.
In line with our methylation results, the oscillation of the nucle-
osome positioning signal at cell-type-specific CTCF sites is
much flatter than the strong alternating enrichment and deple-
tion characteristic of the cCTCF sites. We observe regular posi-
tioning surrounding cCTCF sites using nucleosome occupancydata derived from MNase digestion in either a lymphoid or
myeloid cell line; we further confirm this observation using nucle-
osome positions derived from the integration of ChIP-seq data
for six histone modification marks (Mammana et al., 2013) ob-
tained from the same sorted primary cell samples used for the
DNAmethylation analysis (Figure S4). We conclude that both nu-
cleosomes and DNAmethylation are stably configured at cCTCF
across cell types, but not at unoccupied sites (Chen et al., 2012).
Development of Nucleosome-Influenced Methylation
Patterns
Visual inspection of Figure 4A reveals a progressive increase
in the amplitude of oscillation in the methylation signal, corre-
sponding to B lymphocyte development. To facilitate compari-
son across many samples, we define an objective measure
of nucleosome influence based on the difference in methyla-
tion levels between the constitutively nucleosome-occupied
DNA and the adjacent linker DNA (Figure S5; Experimental
Procedures).
In both B and T lymphocytes, the oscillatory methylation
pattern at cCTCF sites becomes more pronounced with succes-
sive stages of development while global average methylation
levels decline (Figure 6A). Differential methylation analysis over
five stages of B lymphocyte differentiation and activation reveals
enrichment of significant methylation gains at linker DNA andCell Reports 17, 2101–2111, November 15, 2016 2105
Figure 5. mCH in T Lymphocytes
mCH occurs between nucleosomes (black) in naı¨ve T lymphocytes (red), but
not memory T lymphocytes (green and blue). Positive and negative methyl-
ation values correspond to cytosines on the plus and minus strand, respec-
tively. Values are aggregated across 23,710 constitutively occupied CTCF
sites.losses at nucleosome-associated DNA (Figure S6). This progres-
sive shift of methylation from nucleosomes to linkers in longer-
lived lymphocytes is consistent with the idea of a reciprocal
methylation/nucleosome relationship that builds over time.
In contrast to the methylation trends seen in developing lym-
phocytes, the oscillating methylation pattern near cCTCF in the
myeloid lineage is less varied and shows no consistent trend
(Figures 6A and 6C).
Neoplastic transformation results in increased lineage-spe-
cific differences in linker methylation bias (Figures 6B and 6C).
Cancers derived from the lymphoid lineage reflect a continued
shift of methylation from nucleosomes to linkers, in both ex-
perimentally induced EBV (Epstein-Barr virus) immortalization
and primary lymphoid tumor samples (MCL, CLL, and MM).
Myeloid-derived cancer samples (APL and AML), however,
display a methylation oscillation amplitude that is either compa-
rable to that of normal samples from that lineage or substantially
decreased, corresponding to increased global methylation
levels.
DISCUSSION
DNA methylation has a direct role in regulating cell phenotype,
for example, by enforcing CD4 repression that defines the differ-
ence between cytotoxic and helper T cell subsets (Sellars et al.,
2015). We and others have shown that methylation is tightly
coupled to structural features of the genome and that myeloid
and lymphoid cells differ substantially in their usage of methyl-
ation (Bock et al., 2012; Bro¨ske et al., 2009; Ji et al., 2010; Smith
andMeissner, 2013). Localized changes in methylation influence
nucleosome stability (Jimenez-Useche et al., 2013) and affect
CTCF binding, altering chromatin topology (Flavahan et al.,
2016; Ito et al., 2013). From transcription-factor-binding site
footprints to nucleosomes, LADs, and X chromosome inactiva-
tion, methylation varies among cell types at multiple scales.
Given this diversity and the existence of multiple methylation
readers and writers (He and Ecker, 2015), the ways in which
methylation influences phenotype are likely numerous and
pleiotropic.2106 Cell Reports 17, 2101–2111, November 15, 2016During hematopoietic development, DNA methylation pat-
terns diverge. Methylation bias toward nucleosome-free DNA in-
creases progressively with T and B lymphocyte development
while global methylation levels steadily decline. In contrast, CG
methylation appears quite stable during differentiation and
activation of both neutrophils and macrophages in the myeloid
lineage. Declining global methylation levels in developing lym-
phocytes likely reflect the emergence of partially methylated do-
mains, which to our knowledge have not been reported in normal
cells of the myeloid lineage.
Methylation measurements in leukemias and lymphomas from
both lineages are heterogeneous, consistent with the genetic
heterogeneity typically observed in cancer samples. The methyl-
ation profiles of malignant cells are likely to vary substantially
from cell to cell and among samples from different individuals.
However, we see general trends here as well. As a group,
lymphoid-derived neoplasms continue to lose CG methylation,
whereas myeloid cancers have significantly elevated levels of
mCH. This observation has potential clinical relevance, as deme-
thylating agents used as chemotherapeutics (Jasielec et al.,
2014) could have different effects in myeloid leukemias versus
lymphoid malignancies.
The diffuse non-CGmethylation we observe is strongly biased
toward linker DNA, strongly depleted from LADs, and occurs
specifically in all naive T cell samples and the UHPs. Although
the spatial enrichment patterns reflecting nucleosome occu-
pancy are similar for mCG and mCH, the occurrence of high
levels of diffuse mCH only in specific cell types suggests some
degree of independence in the processes governing methylation
in CG and non-CG contexts. The cell-type-specific occurrence
and association with structural features of the genome further
support the interpretation that mCH is a biological phenomenon
and not merely a technical artifact.
We showed that mCH levels across samples and cell types are
not dependent upon bisulfite conversion rate, given a passably
effective bisulfite treatment. Therefore, we suggest that bisulfite
conversion efficiency for WGBS studies should be reported
based on proper controls using known fully methylated and fully
unmethylated DNA and not as the fraction of non-converted non-
CG cytosines, as commonly done.
We note that many of the same cell types high in mCH,
such as naive T cells, stem cells, and neurons, also have
higher reported levels of hydroxymethylation (Booth et al.,
2012; Khare et al., 2012; Tsagaratou et al., 2014). As this de-
rivative of methylation also protects cytosines from bisulfite
conversion, WGBS does not distinguish methylation from hy-
droxymethylation, and it is likely that a small fraction of the
methylation we report here is due to hydroxymethylation (Yu
et al., 2012).
The vast majority of mCH occurs as CA dinucleotides. Deam-
ination of unmethylated cytosine results in uracil, which is effi-
ciently recognized and repaired, but deamination of methylated
cytosine (mC) produces thymine. In amCG dinucleotide context,
deamination on one strand creates a T:G mismatch that may be
repaired either to the original C:G pair or to a new T:A pair,
yielding amCA dinucleotide on the strand opposite the deamina-
tion event. CA dinucleotides resulting from this process (on an
evolutionary timescale) may remain susceptible to methylation
Figure 6. Nucleosome Influence and
DNA Methylation in Lymphoid and Myeloid
Development
Nucleosome influence (y axis) is defined as the
difference in methylation between nucleosome-
occupied DNA and the adjacent linker DNA at
cCTCF. Data are aggregated across 23,710
constitutively occupied CTCF sites.
(A) Normal development in two cell types from
each lineage. Two replicates of B lymphocyte
development: 0, UHP; 1, pre-B; 2, naive B cell; 3,
germinal center B cell; 4, memory B cell; 5, plasma
cell. T lymphocytes: CD4+ (gray) and CD8+ (black).
1, naive T cell; 2, central memory T cell; 3, effector
memory T cell. Neutrophil development: 1,
promyelocyte; 2, metamyelocyte, 3, banded
neutrophil; 4, segmented neutrophil; 5, resting
neutrophil; 6, GTX-activated neutrophil. Monocyte/
macrophage development: 1, monocyte; 2, resting
macrophage (M0); 3, activated macrophages
(red:M1; orange:M2).
(B) Neoplasms derived from lymphoid and myeloid
lineages.
(C) Comparison across cell types. Numbers indi-
cate developmental order as in (A).
See also Figure S5.
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under certain conditions, such as high local concentration or
polymerization of DNA methyltransferases (Rajavelu et al.,
2012). This may provide an explanation for the strong bias for
CA context in diffuse mCH.
The biochemical basis of non-CG methylation in human DNA
is unclear. Inmouse embryonic stem cell lines, depletion of either
DNMT3A or DNMT3B decreases mCH, whereas depletion of
DNMT3L, which does not have a functioning methyltransferase
domain, increases mCH levels (Ramsahoye et al., 2000; Tiede-
mann et al., 2014). In contrast, in germ cells of male mice, muta-
tion of DNMT3L causes severe loss of mCH, which is normally
prevalent in this cell type (Ichiyanagi et al., 2013; Vlachogiannis
et al., 2015). Possible functional roles for mCH in these contexts
remain to be investigated.
The molecular mechanisms of CG methylation have been
described using structural and functional studies (Guo et al.,
2015; Jia et al., 2007). Although there is substantial overlap in
the roles of all three mammalian DNMTs, multiple distinct regu-
latory pathways have been described for each (Jurkowska
et al., 2011). There exist numerous direct and indirect interac-
tions among the readers and writers of histone modifications
and DNA methylation, providing physical links and mechanistic
explanations for the self-reinforcing loops that appear common
in epigenetic regulation (Du et al., 2015).
Limited DNA accessibility due to nucleosome occupancy or
association with the nuclear lamina provides a simple explana-
tion of the methylation patterns we observe, both CG and non-
CG. Alternatively, DNA methylation may occur in conjunction
with nucleosome translocation as part of an active remodeling
process that leaves methylated DNA in its wake, as already
demonstrated in vitro (Felle et al., 2011). Local DNA methylation
patterns may alter the stability of a larger CTCF-nucleosome
complex or otherwise contribute to chromatin structure. Further-
more, methyltransferases can remain bound to DNA whether
catalytically active or not (Jin et al., 2012; Sharma et al., 2011),
raising the possibility of a structural contribution to chromatin,
not only for methylated DNA but also for the enzymes respon-
sible for methylation.
Our observation of distinct DNA methylation patterns in
different cell lineages parallels the differences seen across the
eukaryotic domain. DNA methylation is evolutionarily ancient,
with different species developing novel applications. Phyloge-
netic analysis indicates that the common ancestor of all plants,
animals, and fungi possessed a full complement of DNA methyl-
ation machinery, including the DNA methyltransferases DNMT1
and DNMT3 and a chromomethylase (Zemach et al., 2010).
Whereas some species, such as S. cerevisiae, have dispensed
with DNA methylation, those species that retain methyltrans-
ferases commonly share a core set of methylation features,
augmented with species-specific variations. For example, gene
body methylation (Zemach et al., 2010) and a bias toward linker
DNA over nucleosomal DNA appear nearly universal, whereas
usage of mCH appears more variable (Huff and Zilberman,
2014). Our results support the view that the maintenance of
DNA methylation patterns is fundamentally different between
blood-cell lineages and that epigenetic mechanisms may differ
substantially between distinct cellular lineages within a multicel-
lular organism as they do among different species.2108 Cell Reports 17, 2101–2111, November 15, 2016The functional relevance of specific epigenetic differences
among cell types remains to be fully characterized. The large
collection of BLUEPRINT WGBS datasets, including several
well-defined stages of maturation and additional cell types not
discussed here, provides a resource for understanding normal
development and a basis for comparison with other cell types
and disease states. The accompanying gene expression data
and genome-wide maps of histone modifications and DNA
accessibility from the same primary samples will aid in these
efforts. We expect that a holistic consideration of the diverse
components of an epigenome will be necessary for the sensible
interpretation of the interdependent epigenetic phenomena
directing the expression of our genomic program.
EXPERIMENTAL PROCEDURES
Whole-Genome Bisulfite Sequencing
The BLUEPRINT project received ethical review regarding human and animal
subjects and genetic data handling. Additionally, approval was obtained at
each institute by their respective local ethical review committees. Whole-
genome bisulfite sequencing was conducted at the Centre Nacional d’Ana`lisi
Geno`mica as described in Kulis et al. (2015). After cell sorting, genomic DNA
libraries were constructed using the Illumina TruSeq Sample Preparation kit
(Illumina) following the manufacturer’s standard protocol. DNA was then
exposed to two rounds of sodium bisulfite treatment using the EpiTect Bisulfite
kit (QIAGEN), and paired-end DNA sequencing was performed using the
Illumina Hi-Seq 2000.
We used the GEM mapper (Marco-Sola et al., 2012) with two modified ver-
sions each of the human (GRCh37) and viral reference genomes: one with all
C’s changed to T’s and another with all G’s changed to A’s. Reads were fully
converted in silico prior to mapping to the modified reference genomes, and
the original reads were restored after mapping. The first few bases from
each read have been shown to have a slightly higher probability of being called
as methylated (Schultz et al., 2015), so we trimmed the first ten bases from
each read. Heterozygous positions, positions with a genotype error probability
greater than 0.01, and positions with a read depth greater than 250 were
filtered out. Only cytosines with six or more reads informative for methylation
status were considered. On average, half of the reads from either strand will be
informative for methylation status at a given position, so minimum coverage is
typically greater than 12.
Methylated and unmethylated cytosine conversion rates were determined
from spiked-in bacteriophage DNA (fully methylated phage T7 and unmethy-
lated phage lambda). Five samples were excluded based on conversion rates
<0.997, supported by visual inspection of CG and non-CG methylation plots.
The over-conversion rates for all samples based on methylated phage T7
DNA were 5%.
Methylated non-CGs were defined as those cytosines with at least two un-
converted reads and amethylation probability greater than two SDs, where the
probability of the following base being a guanine was at least two orders of
magnitude smaller than the most probable base. The fraction of mCH for
each sample is calculated as the number of methylated non-CG cytosines
divided by the total number of non-CG cytosines with six or more reads infor-
mative for methylation status.
mCH Spike Detection
Spikes are called in mCH data where the mean methylation value in a sliding
window of ten non-CG cytosines exceeds 20%. Only non-CGs with six or
more reads informative for methylation are considered.
Additional WGBS Data
Additional WGBS data for stem cell lines H1 and H9 were generated by
the Roadmap Epigenome Project (Lister et al., 2009). WGBS data for
stem cell samples (HUES64 cell line) were downloaded from the GEO, acces-
sion numbers GSM1112840 and GSM1112841. WGBS data for normal and
EBV-transformed B lymphocytes were previously published (Hansen et al.,
2014).
Differential Methylation Analysis
Pairwise sample comparisons were made to determine which sites underwent
significant changes in methylation level at each step of B lymphocyte develop-
ment. All positions that passed quality filtering andwere called as homozygous
CGs in both samples were evaluated. Significance in the difference between
samples in the ratio of converted to unconverted reads at each CG was
assessed using Fisher’s exact test if any expected values of the contingency
table were less than ten. Otherwise, a chi-square test was used. Results
were adjusted for multiple comparisons using the false discovery rate method
(Benjamini and Yekutieli, 2001).
Measuring Oscillation Amplitude
To facilitate high-throughput comparison of many samples, an automated pro-
cedure was developed to measure the amplitude of the oscillating methylation
signal. To measure amplitude, we must first determine the distance from the
CTCF-binding motif of the first peak and the first valley in the methylation
signal. Both the period of oscillation and the average methylation levels differ
among samples and cell types, so measuring amplitude assuming a fixed
period or by using the difference between the maximum andminimummethyl-
ation values within a specific distance are unlikely to give good results. Our
signal is further complicated by noise and periodic components at multiple
scales. Wavelet-based transformation is commonly used in digital signal pro-
cessing to smooth noisy data and to identify and localize periodic compo-
nents, making it ideal for this purpose.
A multi-resolution analysis (Percival and Walden, 2006) using the Daube-
chies wavelet transform (WT) filter of length 16 was used to separate the
methylation signal into two distinct components: the average trend in the
signal (a wide ‘‘V’’ with lower methylation levels immediately surrounding the
occupied CTCF site, gradually increasing to genome-wide average methyl-
ation levels within 1 or 2 kb) and the details containing the oscillatory compo-
nent of the signal at nucleosome scale (Figure S5). Peak and valley positions
relative to the CTCF motif were determined using this transformed detail
signal. Amplitudes were computed from the original (untransformed) data us-
ing the difference in averages of the 10 bp surrounding the WT-identified peak
and valley to smooth out local fluctuations (specifically the known 8–10 bp
periodicity inmethylation levels; Lister et al., 2009). The wavelet transformation
was implemented using the R ‘‘wavelets’’ package (Percival and Walden,
2006; R Development Core Team, 2014).
Although we refer to oscillation amplitude in terms of nucleosome influence
on methylation, we note that it is determined based only on the methylation
signal and does not consider explicit information about nucleosome position.
Nucleosome Positioning Data
Nucleosome positions for ENCODE cell lines GM12878 (lymphoblastoid) and
K562 (myeloid) were inferred from MNase sequencing reads, normalized to
input read levels described in Valouev et al. (2011), and downloaded from
the University of California, Santa Cruz (UCSC) genome browser. Nucleosome
positions for BLUEPRINT samples derived from six histone modification ChIP-
seq experiments using NucHunter (Mammana et al., 2013) were downloaded
from the BLUEPRINT data portal. DNAmethylation informationwas not used in
the comparison of nucleosome localization.
Visualization
Whole-genome DNA methylation and nucleosome positioning data were
aligned to CTCF-binding motifs and plotted for visual inspection. To preserve
binding orientation information for CTCF, data surrounding motifs that
occurred on the minus strand were reversed. Non-CG methylation levels
were computed separately for the strand containing the CTCF-binding motif
and the opposite strand. Methylation levels for the opposite strand are plotted
as negative values to facilitate visual analysis.
CTCF-Binding Sites
Occupied CTCF-binding sites were identified by Li et al. (2013) by scanning
ChIP-seq peaks using a position-specific scoring matrix for CTCF motifs.Peaks that were detected in at least 95% of ENCODE cell lines were defined
as constitutively occupied (cCTCF). We defined lymphoblastoid-specific sites
as those present in the GM12878 (lymphoblastoid) cell line, but not in the H1
(human embryonic stem cell) or Nhek (epidermal keratinocyte) cell lines.
Stem-cell-specific and skin-cell-specific sites were similarly defined. As a
negative control, unoccupied sites were defined as those specifically occu-
pied in another cell type.
Data Availability
Data generated by the BLUEPRINT project are available through several chan-
nels, including genome browsers, Biomart, and directly through the BLUE-
PRINT portal. Links to data sources are available at the BLUEPRINT website:
http://www.blueprint-epigenome.eu.
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